Health Condition 1: D631- Anemia in chronic kidney disease
Conditions
Interventions
Intervention1: Clinical pharmacist managed dosing of erythropoietin and iron sucrose: Patients undergoing hemodialysis will receive erythropoietin and iron sucrose according to a pharmacist-managed do
Sponsors
KLE College of Pharmacy Belagavi
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adults equal to and above 18 years of age. 2.Patients with Chronic Kidney Disease (CKD) on maintenance hemodialysis. 3.Patients diagnosed with anemia and receiving erythropoietin therapy (with or without iron supplementation). 4.Clinically stable patients able to comply with study procedures. 5.Patients who provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women. 2.Patients with active bleeding disorders or recent (within 3 months) major blood transfusion. 3.Patients with uncontrolled hypertension or severe cardiovascular instability. 4.Patients with active infection, malignancy, or other comorbidities likely to interfere with anaemia management. 5.Patients with known hypersensitivity to erythropoietin or iron preparations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To develop and test a clinical pharmacist?managed dosing algorithm for optimizing erythropoietin and iron therapy to correct and maintain hemoglobin within the target range (10?11.5 g/dL) in patients undergoing hemodialysis.Timepoint: Baseline (pre-intervention) and monthly follow-ups for 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of the pharmacist-managed algorithm on erythropoietin dose requirements compared with baseline prescribing.Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months.;To assess changes in iron parameters (serum ferritin, transferrin saturation) following algorithm-based interventions.Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months.;To determine the proportion of patients requiring red blood cell transfusions before and after algorithm implementation.Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months.;To assess the safety of the algorithm by monitoring adverse drug reactions, iron overload, and rapid hemoglobin rises.Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months.;To evaluate the acceptance rate of pharmacist recommendations by nephrologists.Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months.;To assess the feasibility of implementing the dosing algorithm in a hemodialysis setting (recruitment rate, retention, time per patient review).Timepoint: Baseline, monthly follow-ups, and final assessment at 6 months. | — |
Countries
India
Contacts
Public ContactDr Geetanjali S Salimath
KLE College of Pharmacy Belagavi
Outcome results
None listed